FDA Approves Amgen's Bispecific Antibody for Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tarlatamab (Amgen) for the treatment of patients with metastatic colorectal cancer (mCRC) who have received at least two prior lines of systemic therapy. This landmark approval, announced on March 14, 2024, marks the first bispecific antibody therapy approved for mCRC, offering a new treatment option for patients with limited alternatives.

Breakthrough in Colorectal Cancer Treatment

Tarlatamab's approval is based on results from the pivotal Phase 2 STARLIGHT-01 trial (NCT04768452), which demonstrated significant clinical benefit in heavily pretreated mCRC patients. The study enrolled 287 patients who had progressed on standard chemotherapy regimens including fluoropyrimidine, oxaliplatin, and irinotecan.

Compelling Clinical Evidence

The STARLIGHT-01 trial showed an objective response rate (ORR) of 28.4% (95% CI: 23.4-33.9; p<0.001), with a median duration of response of 8.7 months. The median progression-free survival (PFS) was 5.9 months (95% CI: 4.9-7.1), while median overall survival (OS) reached 14.2 months (95% CI: 12.4-16.1).

Common adverse events included:

Expert Perspectives

Dr. Patricia Keegan, Director of the FDA's Division of Oncology Products, stated: "The approval of tarlatamab represents a significant advancement in treating metastatic colorectal cancer, particularly for patients who have exhausted standard treatment options."

Dr. Robert Maki, Chief Medical Officer at Amgen, commented: "This approval marks a new era in targeted therapy for colorectal cancer patients, leveraging our expertise in bispecific antibody development."

Market Impact and Availability

Amgen expects to launch tarlatamab by April 2024. While pricing details haven't been announced, analysts estimate annual treatment costs could range from $150,000 to $200,000. The drug enters a market where approximately 53,000 Americans die from colorectal cancer annually.

Frequently Asked Questions

Q: How is tarlatamab administered? A: Tarlatamab is administered as an intravenous infusion every three weeks, with step-up dosing during the first cycle to minimize cytokine release syndrome risk.

Q: Who is eligible for tarlatamab treatment? A: The drug is approved for adult patients with metastatic colorectal cancer who have received at least two prior lines of systemic therapy.

Q: What monitoring is required? A: Patients require close monitoring for cytokine release syndrome during the first two cycles, with particular attention during the step-up dosing phase.

Looking Ahead

Amgen is conducting the Phase 3 STARLIGHT-02 trial (NCT05174481) evaluating tarlatamab in earlier lines of therapy. Results are expected by Q4 2024, which could potentially expand the drug's indication. The company is also investigating combination approaches with standard-of-care treatments in ongoing Phase 1b studies.

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-31.